Virpax says that it has acquired exclusive worldwide rights to Nanomerics’s molecular envelope technology (MET) for use with Virpax’s VRP324 intranasal dry powder cannabidiol (CBD) for the treatment of epilepsy. According to Virpax, Nanomerics is currently conducting preclinical studies of VRP324, which Virpax plans to develop for the treatment of seizures due to tuberous sclerosis complex (TSC), Lennox-Gastaut syndrome and Dravet syndrome in both adult and pediatric patients.
The company is already developing several other candidates based on Nanomerics technology, including AnQlar (MMS019) nasal dry powder “masking spray,” which it envisions as an OTC barrier for protection against respiratory viruses like influenza and SARS-CoV-2, and Envelta intranasal enkephalin for the treatment of pain.
Virpax Chairman and CEO Anthony P. Mack commented, “We believe VRP324 is the first step toward building our neurological disorder therapy pipeline, expanding the use of our novel delivery platform technologies to multiple categories of neurology. Our Envelta IND enabling studies completed by the National Center for Advancing Translational Sciences as a part of our Cooperative Research and Development Agreement, have determined that the MET intranasal delivery formulation bypasses the liver. Consequently, we believe that since the CBD will not be metabolized in the liver, this may reduce the concern of drug-to-drug interaction and/or the need to adjust the dosage of other related medications.”
Read the Virpax Pharmaceuticals press release.
